The Anti-APP Antibody products are intended for Alzheimer's disease research and consist of affinity-purified IgG antibodies that recognize variants of the amyloid precursor protein (APP). These APP antibodies are raised in rabbit or mouse using synthetic peptides and can be applied to Western blot (WB) detection or immunoprecipitation (IP) of the indicated APP protein variants.
The accumulation of amyloid-beta protein plaques in the cerebral cortex of Alzheimer's disease (AD) patients is proposed to result from an excess of the amyloid precursor protein (APP) as well as its aberrant cleavage, leading to the Alzheimer disease etiology. Over 50 different mutations in the APP gene have been linked with early-onset Alzheimer disease. The APP is cleaved by beta- and gamma-secretase via the amyloidogenic pathway, which leads to production of amyloid-beta and soluble APP-beta (sAPP-beta); cleavage by alpha-secretase via the nonamyloidogenic pathway results in sAPP-alpha. Several mutations in the APP gene can give rise to variants of both sAPP-alpha and sAPP-beta.